Neuroscience News -
11 Jun 2019 18:56
Blocking the activity of interleukin-1 in mouse models of complex regional pain syndrome (CRPS) helped reverse symptoms. Researchers say patients with CRPS should respond to immune-based treatments which reduce some of the disease features.
Share this Article